Efficacy and safety of initial combined therapy with metformin plus a dipeptidyl peptidase-4 inhibitor versus metformin monotherapy in type 2 diabetes mellitus: a systematic review and meta-analysis of phase 3 randomised controlled trials

被引：0
|
作者：
Tangney, N. [1 ]
De Buitleir, C. [1 ,2 ,3 ]
O'Brien, T. [1 ,2 ]
Liew, A. [1 ,2 ,3 ]
机构：
[1] Galway Univ Hosp, Galway, Ireland
[2] NUIG, Discipline Med, Galway, Ireland
[3] Portiuncula Univ Hosp, Galway, Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2019年 / 188卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P132
引用
收藏
页码：S248 / S248
页数：1
相关论文
共 50 条
  • [41] Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis
    W. Gao
    Q. Wang
    S. Yu
    Journal of Endocrinological Investigation, 2016, 39 : 1061 - 1074
  • [42] Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomised controlled trials
    Sakurai, R.
    EUROPEAN HEART JOURNAL, 2014, 35 : 43 - 43
  • [43] Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus
    Fan, Yujuan
    Zhang, Yu
    Li, Xuesong
    Zheng, Hui
    Song, Yuping
    Zhang, Ning
    Shen, Chunfang
    Fan, Xiaofang
    Ren, Fengdong
    Shen, Jiayi
    Ren, Guoguang
    Yang, Jialin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 4679 - 4683
  • [44] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
    Pratley, R. E.
    Kipnes, M. S.
    Fleck, P. R.
    Wilson, C.
    Mekki, Q.
    DIABETES OBESITY & METABOLISM, 2009, 11 (02): : 167 - 176
  • [45] Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis
    Kamrul-Hasan, A. B. M.
    Dutta, Deep
    Nagendra, Lakshmi
    Sharma, Meha
    Patra, Shinjan
    Bhattacharya, Saptarshi
    MEDICINE, 2024, 103 (28) : e38870
  • [46] Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
    Goldstein, Barry J.
    Feinglos, Mark N.
    Lunceford, Jared K.
    Johnson, Jeremy
    Williams-Herman, Debora E.
    DIABETES CARE, 2007, 30 (08) : 1979 - 1987
  • [47] Weekly Versus Daily Dipeptidyl Peptidase 4 Inhibitor Therapy for Type 2 Diabetes: Systematic Review and Meta-analysis
    Yamada, Tomohide
    Shojima, Nobuhiro
    Noma, Hisashi
    Yamauchi, Toshimasa
    Kadowaki, Takashi
    DIABETES CARE, 2018, 41 (04) : E52 - E55
  • [48] The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials
    Ling, Juan
    Cheng, Peng
    Ge, Long
    Zhang, Ding-hua
    Shi, An-chen
    Tian, Jin-hui
    Chen, Ya-jing
    Li, Xiu-xia
    Zhang, Jing-yun
    Yang, Ke-hu
    ACTA DIABETOLOGICA, 2019, 56 (03) : 249 - 272
  • [49] The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials
    Juan Ling
    Peng Cheng
    Long Ge
    Ding-hua Zhang
    An-chen Shi
    Jin-hui Tian
    Ya-jing Chen
    Xiu-xia Li
    Jing-yun Zhang
    Ke-hu Yang
    Acta Diabetologica, 2019, 56 : 249 - 272
  • [50] Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus Patients with Moderate to Severe Renal Impairment: A Systematic Review and Meta-Analysis
    Cheng, Dongsheng
    Fei, Yang
    Liu, Yumei
    Li, Junhui
    Chen, Yuqiang
    Wang, Xiaoxia
    Wang, Niansong
    PLOS ONE, 2014, 9 (10):
12345